Skip to main content

GENES Y VIAS DE SEÑALIZACION EMERGENTES EN EL DESARROLLO Y EL CANCER DE TIROIDES

SAF2016-75531-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genomic and epigenomic profile of thyroid cancer

  • Acuña-Ruiz, Adrián
  • Carrasco-López, Carlos
  • Santisteban, Pilar
Thyroid cancer is the most common malignancy of the endocrine system, and its incidence has been steadily increasing. Advances in sequencing have allowed analysis of the entire cancer genome, and has provided new information on the genetic lesions and modifications responsible for the onset, progression, dedifferentiation and metastasis of thyroid carcinomas. Moreover, integrated genomics has advanced our understanding of the development of cancer and its behavior, and has facilitated the identification of new genetic mutations and molecular pathways. The functional analysis of epigenetic modifications, such as DNA methylation, histone acetylation and non-coding RNAs, have contributed to define new regulatory mechanisms that control cell malignancy in thyroid cancer, especially aggressive forms. Here we review the most recent advances in genomics and epigenomics of thyroid cancer, which have resulted in a new classification and interpretation of the initiation and progression of thyroid tumors, providing new tools and opportunities for further investigation and for the clinical development of new treatment strategies., This work was supported by grants PID2019-105303RB-I00/AEI/10.13039/501100011033 from the Ministerio de Ciencia e Innovación (MICIN), Spain; B2017/BMD-3724 from Comunidad de Madrid; and GCB14142311CRES from Fundación Española Contra el Cáncer (AECC). A.A-R holds a postdoctoral contract of GCB14142311CRES from Fundación Española Contra el Cáncer (AECC) and C.C-L has an FPI fellowship associated with Grant SAF2016-75531-R/FEDER from MICIN., Peer reviewed